Vonoprazan

Vonoprazan

Vonoprazan

Chemical compound


Vonoprazan, sold under the brand name Voquezna among others, is a first-in-class potassium-competitive acid blocker medication.[2] Vonoprazan is used in form of the fumarate for the treatment of gastroduodenal ulcer (including some drug-induced peptic ulcers) and reflux esophagitis, and can be combined with antibiotics for the eradication of Helicobacter pylori.[2] It is a potassium-competitive acid blocker.[1]

Quick Facts Clinical data, Trade names ...

It was approved in Japan in February 2015,[3][4] and in Russia in April 2021.[5] Vonoprazan was approved for medical use in the United States in November 2023.[1][6] Co-packaged combinations of vonoprazan with amoxicillin and vonoprazan with amoxicillin and clarithromycin are available.[7][8]

Medical uses

Vonoprazan is indicated for healing of all grades of erosive esophagitis and relief of heartburn associated with erosive esophagitis in adults; to maintain healing of all grades of erosive esophagitis and relief of heartburn associated with erosive esophagitis in adults; in combination with amoxicillin and clarithromycin for the treatment of Helicobacter pylori (H. pylori) infection in adults; in combination with amoxicillin for the treatment of H. pylori infection in adults.[1][7][9]

Society and culture

Names

Vonoprazan is the international nonproprietary name (INN).[10]


References

  1. "Voquezna- vonoprazan fumarate tablet". DailyMed. 8 November 2023. Retrieved 20 November 2023.
  2. Garnock-Jones KP (2015). "Vonoprazan: first global approval". Drugs. 75 (4): 439–43. doi:10.1007/s40265-015-0368-z. PMID 25744862. S2CID 43293048.
  3. "Takecab Now Available for the Treatment of Acid-related Diseases in Japan". Takeda Pharmaceuticals (Press release). 26 February 2015. Archived from the original on 26 October 2023. Retrieved 20 November 2023.
  4. "Russian State Register of Medicines. Vocinti (vonoprazan) Film-Coated Tablets. Full Prescribing Information". grls.rosminzdrav.ru (in Russian). Takeda Pharmaceutical Company Limited. Archived from the original on 18 February 2023. Retrieved 18 February 2023.
  5. "Drug Approval Package: Voquezna". U.S. Food and Drug Administration (FDA). 8 June 2022. Retrieved 3 February 2024.
  6. World Health Organization (2012). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 68". WHO Drug Information. 26 (3). hdl:10665/109813.
  • Clinical trial number NCT04124926 for "Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Erosive Esophagitis" at ClinicalTrials.gov
  • Clinical trial number NCT04167670 for "Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Helicobacter Pylori Infection" at ClinicalTrials.gov



Share this article:

This article uses material from the Wikipedia article Vonoprazan, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.